Brain-type natriuretic peptide release and seizure activity during vagal nerve stimulation

Markus Rauchenzauner, Edda Haberlandt, Wolfgang Högler, Gerhard Luef

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Vagus nerve stimulation (VNS) has emerged as an effective adjunctive therapy for medically refractory epilepsy when surgery is inadvisable. N-terminal brain-type natriuretic peptide (NT-proBNP) is a potent natriuretic, diuretic, and vasodilatative compound first discovered in the human brain but mainly synthesized in the myocardium. The monitoring of VNS effectiveness in reducing seizure frequency or the detection of possible cardiac adverse effects would be helped by a reliable biochemical marker, which has not been available thus far. We report a four-year-old boy with drug-resistant idiopathic generalized epilepsy whose NT-proBNP levels increased during VNS and seizures.

Original languageEnglish
Pages (from-to)397-9
Number of pages3
Issue number2
Publication statusPublished - Feb 2007


  • Biomarkers
  • Child, Preschool
  • Electric Stimulation Therapy
  • Epilepsy, Generalized
  • Humans
  • Male
  • Natriuretic Peptide, Brain
  • Seizures
  • Vagus Nerve
  • Case Reports
  • Journal Article


Dive into the research topics of 'Brain-type natriuretic peptide release and seizure activity during vagal nerve stimulation'. Together they form a unique fingerprint.

Cite this